EP
IRWD icon

Eversept Partners’s Ironwood Pharmaceuticals IRWD Stock Holding History

Eversept Partners’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-233,667
Closed -$2.65M – 65
2019
Q1 		$2.65M Buy
+233,667
New +$2.61M 0.77% 27

Other funds holding IRWD

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return

Eversept Partners's IRWD Position: Q2 2019 in Review

Eversept Partners sold out of Ironwood Pharmaceuticals (IRWD) in Q2 2019, closing a stake of 233,667 shares — an estimated $2.65M sold.

Eversept Partners first reported a position in IRWD in Q1 2019 and held it in 1 quarter. The position peaked at $2.65M in Q1 2019. 152 funds tracked by Wall St. Rank hold IRWD as of Q2 2019.

  • Eversept Partners reported no remaining Ironwood Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Eversept Partners sold 233,667 Ironwood Pharmaceuticals shares in Q2 2019, an estimated $2.65M.
  • Eversept Partners first reported a position in Ironwood Pharmaceuticals in Q1 2019 and held it in 1 quarter.
  • Eversept Partners's Ironwood Pharmaceuticals position peaked at $2.65M in Q1 2019.
  • 152 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q2 2019.

Based on Eversept Partners's 13F filing for Q2 2019, filed 13 Aug 2019.